Zobrazeno 1 - 10
of 285
pro vyhledávání: '"Alvaro Urbano-Ispizua"'
Autor:
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, Mara Nuding, Marta Soria-Castellano, Paula Barbao, Aleix Prat, Alvaro Urbano-Ispizua, Johannes B. Huppa, Sonia Guedan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controv
Externí odkaz:
https://doaj.org/article/7804df0598d54b5bb293efc2b4f633cf
Autor:
Anna Gaya, Talha Munir, Alvaro Urbano‐Ispizua, Morag Griffin, Jorg Taubel, Jim Bush, Ishir Bhan, Anna Borodovsky, Yue Wang, Prajakta Badri, Pushkal Garg
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 612-624 (2023)
Abstract Complement dysregulation underpins the physiopathology of paroxysmal nocturnal hemoglobinuria (PNH). Cemdisiran, an RNA interference investigational treatment, silences complement component 5 (C5) expression in the liver. Previously reported
Externí odkaz:
https://doaj.org/article/61ecf6a3d4fc4e4b80d5645a8b251397
Autor:
Anthony M. Battram, Aina Oliver-Caldés, Maria Suárez-Lledó, Miquel Lozano, Miquel Bosch i Crespo, Núria Martínez-Cibrián, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 26, Iss , Pp 207-223 (2022)
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at
Externí odkaz:
https://doaj.org/article/85ce7bb7085742eaa47debfe86d2dbc9
Autor:
Alvaro Urbano-Ispizua, Sara Fernández, Pedro Castro, Francesc Fernández-Avilés, Enric Carreras, Adrián Téllez, Valentín Ortiz-Maldonado, Carlos Fernández de Larrea, Julio Delgado, Olaf Penack, Ana Belen Moreno-Castaño, Helena Ventosa, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, J M Nicolás, Gines Escolar, Maribel Diaz-Ricart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicit
Externí odkaz:
https://doaj.org/article/596812ed16e74fdfbda10735d5315b0e
Autor:
Amer Najjar, Manel Juan, Lorena Pérez-Amill, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio, Mireia Bachiller, Anthony Matthew Battram, Sebastian Ciro Carné, Els Verhoeyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/83b56dc8044d43ad9b451d4d44edf564
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/70d4c17f0a8b47849028edc1ec60c781
Autor:
Mireia Bachiller García, Lorena Pérez-Amill, Anthony Battram, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/8a406dfda0404fcbb487f9eb3648f8e6
Autor:
Ibrahim Yakoub-Agha, Christian Chabannon, Peter Bader, Grzegorz W. Basak, Halvard Bonig, Fabio Ciceri, Selim Corbacioglu, Rafael F. Duarte, Hermann Einsele, Michael Hudecek, Marie José Kersten, Ulrike Köhl, Jürgen Kuball, Stephan Mielke, Mohamad Mohty, John Murray, Arnon Nagler, Stephen Robinson, Riccardo Saccardi, Fermin Sanchez-Guijo, John A. Snowden, Micha Srour, Jan Styczynski, Alvaro Urbano-Ispizua, Patrick J. Hayden, Nicolaus Kröger
Publikováno v:
Haematologica, Vol 105, Iss 2 (2020)
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the trea
Externí odkaz:
https://doaj.org/article/2ed21be315d44b1fa8d696f1f61532e3
Autor:
Anthony M. Battram, Mireia Bachiller, Victor Lopez, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio
Publikováno v:
Cancers, Vol 13, Iss 14, p 3534 (2021)
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but
Externí odkaz:
https://doaj.org/article/2c81e485438e433c999851b047d4dd05
Autor:
Belen Lopez-Millan, Rafael Diaz de la Guardia, Heleia Roca-Ho, Eduardo Anguita, Abul B. M. M. K. Islam, Damia Romero-Moya, Cristina Prieto, Francisco Gutierrez-Agüera, Jose Antonio Bejarano-Garcia, Jose Antonio Perez-Simon, Paula Costales, Montse Rovira, Pedro Marín, Silvia Menendez, Mar Iglesias, Jose Luis Fuster, Alvaro Urbano-Ispizua, Fernando Anjos-Afonso, Clara Bueno, Pablo Menendez
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the BM stroma is a major mech
Externí odkaz:
https://doaj.org/article/54a57922b2b743469d7b9ac5626d78f1